Coherus Distances Itself From Biosimilar Interchangeability

US Humira Biosimilars May Feature Designation In 2023

 
• By Dean Rudge

Coherus BioSciences has had its say on the prospect of interchangeability for Humira biosimilars, shortly after Boehringer Ingelheim announced positive data from a ‘first-of-its-kind’ switching study.

Railway tracks with switches and interchanges at a main line in Germany with geometrical structures black and white
A lack of interchangeability has not hindered biosimilar uptake in Europe, Coherus argues • Source: Shutterstock

More from Biosimilars

More from Products